Glycolipid containing compositions for use in the treatment of tumors
The invention relates to pharmaceutical compositions comprising α-Gal BOEL for use in treating patients with tumors. The invention also relates to methods of treating tumors using said compositions. The invention discloses that following intratumoral injection of α-Gal BOEL, binding of the natural anti-Gal antibody to de novo expressed tumoral α-Gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumor cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumor specific T cells thereby converting the treated tumor lesions into in situ autologous tumor vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumor resection. In addition to the regression and/or destruction of the treated tumor, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumor. The invention further teaches the enhancement of anti-tumor α-Gal BOEL treatment by the use of antibodies that inhibit the activity of immunological checkpoints molecules.
1. A method of treating a tumor in a subject, comprising:
introducing into the tumor a pharmaceutical composition comprising (9Z,9′Z)-(2R)-3-(((2-(6-((3-(((2R,3R,4R,5S,6R)-3-acetamido-5-(((2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propyl)amino)-6-oxohexanamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl bis(octadec-9-enoate).
2. The method as defined in claim 1 , wherein the subject is a human or a mouse.
3. The method as defined in claim 1 , wherein the introducing step comprises a procedure selected from: injection, imaging guided injection, endoscopy, bronchoscopy, cystoscopy, colonoscopy, laparoscopy, and catheterization.
4. The method as defined in claim 1 , wherein the subject was treated previously to surgically remove the tumor.
5. The method as defined in claim 1 , wherein the subject was not treated previously to remove the tumor.
6. The method as defined in claim 1 , wherein said pharmaceutical composition is introduced in an amount such that the tumor undergoes regression or is destroyed.
7. The method as defined in claim 1 , wherein the tumor is a solid tumor, myeloma, or a lymphoma.
8. The method as defined in claim 1 , wherein the tumor is a tumor originating from an organ selected from peritoneum, liver, pancreas, lung, urinary bladder, prostate, uterus, cervix, vagina, bone marrow, breast, skin, brain, lymph node, head and neck, stomach, intestine, colon, kidney, testis, and ovaries.
9. The method as defined in claim 1 , wherein the tumor comprises a primary tumor and/or a metastasis.
10. The method as defined in claim 1 , wherein the tumor comprises melanoma, sarcoma, glioma, or carcinoma cells.
11. The method as defined in claim 1 , wherein the introducing step comprises administering the composition by injection.
12. The method as defined in claim 1 , wherein introducing step comprises administering the composition in one dose or multiple doses.
13. The method as defined in claim 1 , wherein the introducing step comprises administering the composition by topical application.
14. The method as defined in claim 13 , wherein the composition is a topical ointment, topical lotion or topical solution.
15. The method as defined in claim 1 , wherein the composition additionally comprises one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).
16. The method as defined in claim 1 , wherein the composition additionally comprises one or more additional therapeutic agents.
17. The method defined in claim 16 , wherein the one or more additional therapeutic agents comprise one or more systemic inhibitors of immune system down-regulation.
18. The method as defined in claim 17 , wherein the one or more systemic inhibitors of immune system down-regulation is selected from anti-CTLA-4, PD-1 or PD-L1 antibodies.